Array nails $10M milestone; Clinical Data asset sale spurs pharma transition

 @FierceBiotech: GSK's Witty calls for an R&D renaissance. Story | Follow @FierceBiotech

 @JohnCFierce: Basilea awarded $130M from J&J after the pharma company dumped their antibiotic pact--after the trials were messed up. Report | Follow @JohnCFierce

> Array BioPharma says it scored a $10 million milestone in its three-year-old pact with Celgene. Array anticipates initiating a Phase I dose escalation trial in cancer patients with ARRY-382, a small molecule cFMS inhibitor, during the first quarter of 2011. Release

Special Report: The most (and least) efficient Big Pharma companies. Report

> Clinical Data has struck a deal to sell its genetic and pharmacogenomic testing and biomarker development business to Transgenomic for $15.4 million. The deal clears the way for Clinical Data to transition into a pharma company with the expected launch of vilazodone. Story

> ImmunoGen has initiated a randomized Phase I/II clinical trial to evaluate its proprietary product candidate, IMGN901 (lorvotuzumab mertansine), for first-line treatment of small-cell lung cancer in patients with extensive disease. Release

> The Scripps Research Institute and Aileron Therapeutics have forged a pact that will add Scripps Research's "Click" chemistry to Aileron's proprietary stabilized peptide and protein technology platforms, which includes the Stapled Peptide technology. Release

Special Report: The fastest growing therapeutic classes. Chart

> Shares of Angiotech Pharmaceuticals surged on the news that it has entered into a private label product supply agreement with Hologic for soft tissue biopsy instruments manufactured by Angiotech. Release

And Finally... A Canadian biotech company has developed an apple that doesn't start to brown right after you slice it, saying that the new, new apple should make for a better product on supermarket shelves. Story

Suggested Articles

Almirall and Iktos will use the latter's AI technology to design new compounds that tick multiple drug criteria boxes.

Pfizer’s 2017 spinout company SpringWorks has lost president and founder Lara Sullivan, M.D., who has moved over to Pyxis Oncology as its new chief.

In this week's EuroBiotech Report, Sanofi inks $2.5B Synthorx takeover and posts sutimlimab data, Roche shares bispecific results and more.